Cellectis Biotherapeutics (CLLS) Short-Term Debt to Capital

Symbol and logo of brand Cellectis (CLLS)

The linear price action for Cellectis S.A. (CLLS) on the GURU.Markets platform chart is 0.33. The business relies on external CDMO contractors for gene editing, mitigating risks by expanding production capacities. Cellectis S.A. (CLLS) is implementing advanced methods for creating universal cell therapies to make treatment accessible to the masses. The scalability of factory-scale donor product output significantly increases the operational efficiency of this biotech.

CLLS (cellectis.com) Current Liabilities to Capital history from 07/04/2022 to 10/28/2026

Analytical breakdowns for Cellectis S.A.

- price and consensus price forecast:
Price Chart Cellectis S.A.|CLLS - Broker Consensus Forecast
- market capitalization data:
Market Capitalization Cellectis SA|CLLS - Real Price to Acquire Entire Company
- book capitalization data:
Net Assets per Single Share Cellectis S.A.|CLLS - Total Stockholders' Equity|Market Value to Book Value Ratio cellectis.com|CLLS - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity Cellectis S.A.|CLLS - Long-Term Liabilities to Capital|Short-Term Debt to Capital Cellectis S.A.|CLLS - Company Total Indebtedness|Debt to Book Value Cellectis SA|CLLS - Long-Term Debt|Company Current Liabilities Cellectis S.A.
Fundamental company analysis:Cellectis (CLLS)
Manufactured products of Cellectis Biotherapeutics

Defensive portfolio screening requires strict control over the liability structure to minimize credit risks. This indicator measures the share of short-term borrowings in total capital, allowing for an assessment of the company's dependence on immediate refinancing. For Cellectis S.A. (CLLS), this balance is critical, as the cost of patents for allogeneic CAR-T cells requires stable funding without the pressure of urgent debts. The dynamics of the ratio between current loans and capital reflect the actual trajectory of the business's financial stability.

Competitors of Cellectis S.A.

Short-Term Debt to Equity Legend Biotech Inc. LEGN|Short-Term Debt to Capital Ratio Sana Corp (SANA)|Autolus Therapeutics - Short-Term Debt to Capital|allogene.com - Short-Term Debt to Equity Ratio|RNAC (Cartesian Therapeutics, Inc.) - Short-Term Debt to Equity|CRBU: Current Liabilities to Capital|Instil Bio, Inc (TIL) - Short-Term Debt to Equity|GNTA (Genenta Science) - Short-Term Debt to Equity|Short-Term Debt to Equity IPSC (Century Tx)|Current Liabilities to Capital Jasper Bio|SNTI: Short-Term Debt to Capital|Short-Term Indebtedness to Equity adaptimmune.com ADAP|CERO: Short-Term Debt to Equity Ratio|TCRT - Current Liabilities to Capital|Short-Term Debt to Equity Ratio Achilles Tx (ACHL)|CRGX - Ratio of Short-Term Indebtedness to Capital|PSTX (Poseida Therapeutics, Inc.) - Short-Term Debt to Capital|2seventy bio Inc. (TSVT) - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital GRCL (Gracell Biotechnologies Ltd)